Moderate Aortic Stenosis

Definition

Moderate aortic stenosis is calcific or rheumatic valve obstruction that does not meet severe criteria: an aortic-valve area of about 1.0–1.5 cm², a peak velocity of 3.0–3.9 m/s, or a mean gradient of 20–39 mmHg. It is a heterogeneous label. Most patients follow an indolent course and are managed with echocardiographic surveillance every 1–2 years, but a subset with symptoms, adverse structural or functional features, or a high calcium score progresses rapidly and behaves like severe disease. The clinical problem is therefore not the average patient with moderate stenosis but the identification of the at-risk phenotype within it. (sources/TAVR-ModAS-NEJM-2026, rating: very high; sources/vhd-esc-2025, rating: very high)

Key Concepts

Grading and the Limits of the Label

Parameter Moderate range Caveat
Aortic-valve area 1.0–1.5 cm² Area is flow-dependent; low-flow states can make moderate disease look severe and vice versa
Peak velocity 3.0–3.9 m/s Discordance between area and velocity is common and requires a full echocardiographic assessment
Mean gradient 20–39 mmHg Gradient depends on transvalvular flow and ventricular function

At-Risk Features

PROGRESS defined an at-risk feature as a symptom or structural or functional abnormality associated with faster progression or adverse cardiovascular outcomes. At least one was required for enrolment.

Feature Threshold or definition Prevalence in PROGRESS
Valve-related symptoms NYHA class ≥II, chest pain or syncope 96.4%
Reduced LV ejection fraction <60% ~25%
Diastolic dysfunction Grade ≥2 by ASE criteria 43.8%
Low stroke volume index <35 mL/m² 8.4–14.2%
Recent atrial fibrillation Persistent or paroxysmal within 6 months 18.3–20.9%
Elevated natriuretic peptide NT-proBNP >3× upper limit of normal 20.6–22.1%
Elevated aortic-valve calcium >1200 Agatston units in women, >2000 in men 23.2–28.2%

(sources/TAVR-ModAS-NEJM-2026, rating: very high)

The PROGRESS Trial

Element Detail
Population 744 patients aged ≥65 years with moderate AS and ≥1 at-risk feature; mean age 78.4; 39.1% women; STS-PROM 3.0%; 45.6% low surgical risk
Intervention Transfemoral TAVR with SAPIEN 3, SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA versus clinical surveillance
Primary endpoint Death from any cause or heart-failure event, with or without hospitalization, at 2 years
Primary result 16.7% versus 23.9%; risk difference −7.2 percentage points (95% CI −13.1 to −1.3); HR 0.67 (0.48–0.93); P=0.02
Death 8.4% versus 7.3%; HR 1.14 (0.67–1.93)
Heart-failure event 10.8% versus 19.0%; HR 0.55 (0.37–0.81)
HF hospitalization 7.4% versus 14.9%; difference −7.5 percentage points
Primary safety endpoint 5.9% at 30 days, below the 13.7% performance goal (P<0.001)
Surveillance crossover 27.0% underwent AVR by 1 year and 57.4% by 2 years; 81.4% for progression to severe AS

(sources/TAVR-ModAS-NEJM-2026, rating: very high)

Secondary Outcomes and Health Status

Progression during Surveillance

Procedural Safety

Relation to Other Trials

Contradictions / Open Questions

Connections

Sources